ArticleDiabetes, obesity & metabolism2025
Plasma sphingolipids predict advanced liver fibrosis development in patients with type 2 diabetes.
Article in Diabetes, obesity & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Towards spatial lipid profiling by using mass spectrometry: analytical challenges and applications.Analytical and bioanalytical chemistry · 2026Review
- Plasma sphingolipids predict advanced liver fibrosis development in patients with type 2 diabetes.Diabetes, obesity & metabolism · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
aimsPatients with type 2 diabetes (T2D) are at an elevated risk of developing metabolic dysfunction-associated steatotic liver disease (MASLD), with a significant likelihood of progression to advanced liver fibrosis (AF)-a stage linked to adverse outcomes. Considering the critical role of lipids in the pathophysiology of MASLD and AF, we aimed to identify lipidomic biomarkers that could predict the development of AF in individuals with T2D. MATERIALS AND
methodsWe included 67 T2D patients, followed for a mean duration of 10.2 ± 3.9 years. We measured baseline plasma concentrations of 148 molecular species of phospholipids, sphingolipids, and free fatty acids. We assessed the development of AF during the follow-up period using liver stiffness measurement (AF if ≥8.0 kPa). Patients who developed ultrasonographic signs of cirrhosis were classified as having AF.
resultsAF developed in 14 patients (20.9%) during the follow-up period. Univariate analysis revealed that baseline plasma levels of two sphingolipids among 148 lipid species assessed, namely d18:1/18:0 sphingomyelin and d18:0/20:0 dihydroceramide, were significantly predictive of AF development. Machine-learning multivariate approaches identified baseline plasma levels of d18:0/20:0 dihydroceramide and d18:1/18:0 sphingomyelin as the most predictive variables for AF development, independently of follow-up duration, baseline body mass index, and baseline levels of transaminases, gamma-glutamyl transferase, and the fibrosis-4 index.
conclusionsBaseline levels of two plasma sphingolipid species are independent predictors of AF development in patients with T2D. These findings could help identify T2D patients at elevated risk of adverse hepatic and extrahepatic outcomes, potentially allowing for new targeted therapeutic interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.